Johnson & Johnson Halts Four Key Clinical Trials in 2025 Amid Pipeline Restructuring

　　【Pharmaceutical Network Enterprise News】In 2025, many multinational pharmaceutical companies such as Pfizer, Eli Lilly, Takeda, and Sanofi are "streamlining" their R&D pipelines by terminating a large number of clinical trial projects due to reasons like unexpected clinical trial data and strategic adjustments. Notably, after Johnson & Johnson had previously terminated key projects covering areas such as oncology, depression, and rheumatoid arthritis, it recently announced the termination of a significant clinical trial for a product targeting Alzheimer's disease treatment.
 

November 24 news: Johnson & Johnson announced the termination of the phase II clinical trial for its anti-Alzheimer's disease (AD) candidate drug, posdinemab. This antibody drug, which targets tau protein, failed to significantly slow clinical decline in more than 500 patients with early AD, and its core efficacy endpoints did not reach statistical significance.
 

According to reports, posdinemab primarily targets early AD patients. The drug can bind to pathologically phosphorylated tau proteins released by neurons and neutralize them before tau nucleation and spread to other neurons. It has demonstrated potential in reducing tau nucleation and diffusion in both in vivo and in vitro non-clinical studies. On January 8, 2025, Johnson & Johnson announced that posdinemab (JNJ-63733657) had been granted entry into the FDA’s Fast Track program, becoming the second therapy in the company's AD pipeline to enter the fast track.
 

Despite the setback of posdinemab, Johnson & Johnson has not completely withdrawn from AD research and development. The company is advancing another tau-targeted therapy — JNJ-2056. This is an active tau immunotherapy primarily aimed at preclinical AD populations and has now entered phase two clinical trials. Notably, in September this year, Dr. John Reed, a senior executive of Johnson & Johnson's R&D, revealed that the company has other tau-related projects "about to enter clinical trials."
 

In fact, including posdinemab, Johnson & Johnson has terminated at least four key R&D projects this year. On March 7, due to insufficient efficacy, Johnson & Johnson halted the Phase III project of the investigational drug aticaprant for treating major depressive disorder (MDD). On March 10, it was reported that due to a treatment interruption rate as high as 51.1% (compared to 4.7% in the daratumumab group), Johnson & Johnson announced it was relinquishing the option for global licensing, development, manufacturing, and commercialization of the next-generation CD38 antibody HexaBody-CD38 (GEN3014).
 

In August, Johnson & Johnson decided not to continue developing a combination therapy for arthritis patients due to the results of an interim trial failing to show sufficient efficacy. The company had been studying the combination of the drug Nipocalimab with anti-tumor necrosis factor-alpha therapy, which can block inflammation.
 

Overall, the reasons for Johnson & Johnson's termination of projects in 2025 mainly focus on clinical trial data not meeting expectations. The industry believes that as the company has positioned oncology, immunology, and neuroscience as its core global R&D areas, and is concentrating resources to make breakthroughs in critical diseases, new drug development in these fields will continue to advance. At that time, many trials will be terminated for various reasons, but innovative achievements will also continue to emerge.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.